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ABSTRACT 
 
Distal renal tubular acidosis (dRTA) is a tubular disorder with a primary defect of 
urinary acidification and acid excretion in the collecting duct system. Consequently, 
patients develop hyperchloremic metabolic acidosis with an inappropriately alkaline 
urine. Inherited forms of dRTA are due to mutations in at least three distinct genes: 
SLC4A1, ATP6V1B1, ATP6V0A4. Mutations in SLC4A1-(AE1) are inherited either in 
an autosomal dominant manner or in a recessive one. ATP6V1B and ATP6V0A4 
mutations affect two different subunits of the vacuolar H+-ATPase proton-pump, the 
B1 and a4 subunits, and are inherited in an autosomal recessive manner. Clinical 
manifestations of inherited forms of dRTA usually occur during infancy or childhood. 
However, heterozygous carriers of ATP6V1B1 and ATP6V0A4 mutations may have a 
higher risk of developing nephrolithiasis and nephrocalcinosis in adulthood, 
respectively. In full forms of dRTA, patients may present with mild clinical symptoms, 
such as mild metabolic acidosis and incidental detection of kidney stones as well as 
with more severe manifestations such as failure to thrive, severe metabolic acidosis, 
and nephrocalcinosis. Progressive sensorineural hearing loss develops in the 
majority of patients with recessive dRTA (ATP6V1B1 and ATP6V0A4 mutations). 
Some patients with recessive dRTA may also develop abnormal widening of the 
vestibular aqueduct. This review will discuss our current understanding of the 
pathophysiology of inherited forms of dRTA, diagnosis and prognosis of patients, and 
therapy. 
  
Inherited forms of dRTA 
 
2 
 
RENAL ACID EXCRETION 
Next to the ventilation of CO2 by the lungs, the kidneys play a central role in 
the long-term control of acid-base homeostasis. The daily excretion of acid and the 
regeneration of approximately 1 mmol bicarbonate per kg bodyweight (e.g. 70 
mmoles in an average person of 70 kg body weight per day) are critical tasks. The 
importance of these processes becomes most evident in syndromes or diseases 
affecting overall kidney function or more specifically in forms of acquired or inherited 
renal tubular acidosis.  
Maintenance and control of systemic acid-base balance by the kidney is 
achieved through three major processes: 1) the reabsorption of filtered bicarbonate, 
2) the excretion of acid mostly in the form of ammonium and titratable acidity, and 3) 
by the de novo synthesis of bicarbonate to replenish bicarbonate lost in metabolism 
[1].  
The kidneys filter daily about 180 litres of primary urine containing a total of 
approximately 4500 mEq bicarbonate which in a healthy person is entirely 
reabsorbed along the nephron. About 80% of the filtered bicarbonate are reclaimed 
in the proximal tubule via secretion of protons by NHE sodium-proton exchangers 
(mostly the NHE3/SLC9A3 isoform) and proton pumps (H+-ATPases) and, as 
suggested recently the sodium-dependent bicarbonate cotransporter (NBCn2) [2]. 
Because of the luminal activity of carbonic anhydrases (Carbonic anhydrase type IV 
(CAIV)) the formation of CO2 and H2O from HCO3- and H+ is facilitated. CO2 and H2O 
then diffuse into proximal tubule cells where the process is reversed by the cytosolic 
carbonic anhydrase type II (CAII). The resulting HCO3- is released into blood by the 
basolateral sodium-bicarbonate cotransporter (NBCe1/SLC4A4) whereas protons are 
recycled into urine across the luminal membrane (Figure 1). A fraction of bicarbonate 
is also reabsorbed through the paracellular pathway in the proximal tubule driven by 
the luminal accumulation of chloride and the lumen-negative potential.  
The remaining bicarbonate (approx. 20 % of the filtered load) is then 
reabsorbed along the thick ascending limb of the loop of Henle by transcellular 
mechanisms similar to the proximal tubule. 
 
Metabolism consumes bicarbonate (i.e. in the urea cycle) and produces acids 
that require buffering by bicarbonate. The kidney replenishes bicarbonate by de novo 
generation of bicarbonate from ammoniagenesis in the proximal tubule and by 
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hydration of CO2 in acid-secretory type A intercalated cells. In the proximal tubule, 
glutamine is taken up mostly from blood and fueled into ammoniagenesis and 
gluconeogenesis releasing ammonia and bicarbonate ions. Ammoniagenesis is 
stimulated during acidosis (by enhanced glutamine uptake and higher enzymatic 
fluxes) and contributes to the renal adaption. Renal ammonium excretion is a process 
involving several steps. First ammonium is secreted into urine in the proximal tubule 
(a fraction is also released back into circulation), mostly reabsorbed by the Na/K/2Cl-
cotransporter NKCC2 in the thick ascending limb of the loop of Henle, accumulated in 
the interstitium and finally secreted by the cells lining the collecting duct system into 
urine in the form of ammonia (see below). 
 
Final urinary acidification and fine-tuning of renal acid-excretion occurs in the 
collecting system consisting of the connecting tubule, the cortical and medullary parts 
of the collecting duct [3]. The first intercalated cells appear already in the late distal 
convoluted tubule.   
 
Acid-secretory type A intercalated cells not only mediate ammonia excretion 
into urine but are also responsible for urinary acidification coupled to de novo 
synthesis of bicarbonate (Figure 2). CO2 is hydrated with the help of the cytosolic 
CAII forming protons and bicarbonate. Bicarbonate is released into blood via the 
basolateral chloride-bicarbonate exchanger AE1 (Anion exchanger 1, SLC4A1) 
whereas protons are pumped into urine by vacuolar-type H+-ATPases located in the 
luminal membrane [3-4]. As discussed below, rare genetic mutations in SLC4A1 or 
two different subunits of the multimeric H+-ATPase (consisting of more than 14 
subunits with multiple isoforms) cause inherited forms of distal renal tubular acidosis 
(dRTA) [5-7]; Secretion of protons into urine acidifies urine to a maximal pH of around 
4.5 - 4.0. Further acidification of urine is impossible as proton pumps must work 
against a steep proton gradient (intracellular pH 7.2, luminal pH 4.5). However, one 
liter of urine of pH 4.5 contains only 30 µmoles protons, a minute amount compared 
to the requirement to excrete 70 mmoles of acid. Urinary buffers, so-called titratable 
acidity (the term refers to the method to measure titratable acidity by back-titrating 
acidified urine), help to buffer protons and thereby to increase the amount of excreted 
acid. The main “titratable acid» is phosphate, creatinine and urate also contribute to 
variable extents. Proton secretion is also tightly coupled to ammonia secretion where 
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luminal ammonia (NH3) captures free protons and is trapped in urine in the form of 
ammonium (NH4+). Ammonia secretion by intercalated cells (and also by neighboring 
principal cells) is mediated by two related gas channels belonging to the family of the 
rhesus blood group proteins, namely RhBG and RhCG (Figure 2) [8-10]. 
The sum of urinary ammonium plus titratable acidity minus bicarbonate is 
called net acid secretion. For the sake of simplicity, urinary phosphate can be taken 
as approximation for titratable acidity and urinary bicarbonate can be neglected when 
urine pH is below pH 6.5 [8].  
The activity of type A intercalated cells and hence net acid secretion is 
enhanced during acidosis and decreased during alkalosis. 
 
Next to type A intercalated cells, a second type of intercalated cells, type B 
intercalated cells, is expressed in the distal convoluted tubule, connecting tubule and 
cortical collecting duct. These cells harbor the chloride/bicarbonate exchanger 
pendrin (SLC26A4) on their luminal membrane and play an important role in the 
secretion of bicarbonate during alkalosis and the reabsorption of chloride [11-12]. 
The latter may be important for the control of NaCl homeostasis and blood pressure 
control [13-18]. 
 
CASE REPORT 
A 35-year old male patient with recurrent urolithiasis and nephrocalcinosis was 
referred to our stone clinic for metabolic evaluation. He was diagnosed with distal 
renal tubular acidosis when he presented at the age of 6 years with severe metabolic 
acidosis (pH 6.98, bicarbonate 3.3 mmol/l) and alkaline urine pH of 7.0. Ultrasound of 
the kidneys demonstrated bilateral medullary nephrocalcinosis. After careful analysis 
of his pedigree an autosomal recessive inheritance was suspected. Consequently, 
alkali treatment with potassium citrate and sodium bicarbonate was initiated. 
However, due to non-adherence he suffered from repetitive episodes of 
nephrolithiasis during adolescence and young adulthood. Stone analysis revealed 
100% calcium phosphate. Additionally, as a consequence of the repeated pain 
therapy with opioids he became opioid dependent. At presentation in our stone clinic 
he had developed chronic kidney disease KDIGO stage G 3a-b and sensorineural 
hearing loss. Ultrasound of his kidneys demonstrated bilateral nephrocalcinosis 
(Figure 3). Adherence to therapy was still problematic since hypokalemia (serum 
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potassium 3.1 mmol/l) and metabolic acidosis (bicarbonate 15 mmol/l) were still 
present. Bone densitometry indicated osteopenia with normal levels of calcium, 
parathyroid hormone, 25-OH- and 1,25-(OH)2-Vitamin D3. Serum phosphate was low 
(0.67 mmol/l). Genetic analysis in the Department of Genetics at the European 
Georges Pompidou Hospital in Paris revealed a homozygous mutation (p.Gln753*) in 
the ATP6V0A4 gene encoding for the a4 subunit of the vacuolar H+-ATPase. Despite 
ongoing repetitive kidney stone episodes, his kidney function remained stable over 
the last 3 years.  
 
MECHANISMS OF INHERITED FORMS OF DISTAL RENAL TUBULAR ACIDOSIS 
 
Inherited forms of renal acid-base disturbances are rare and caused by 
mutations in transport proteins and enzymes located in acid-secretory intercalated 
cells in the collecting duct system, mutations of components of the angiotensin II - 
aldosterone system regulating renal acid excretion, or by mutations leading to 
malformations of the kidney [1]. The various types of renal tubular acidosis affect 
mostly specific transport pathways localized in distinct nephron segments which 
provide the basis for the nomenclature of these acid-base disturbances. In the 
following we will focus on defects underlying type I renal tubular acidosis (RTA I, 
classic type) or distal renal tubular acidosis (dRTA).    
 
Classic dRTA is characterized by the inability to acidify urine below pH 5.3 in 
the presence of metabolic acidosis. Consecutively, the excretion of ammonium and 
titratable acids is also reduced leading to an overall reduction in urinary acid 
excretion [1]. Patients develop hyperchloremic metabolic acidosis usually with a 
normal anion gap often associated with hypokalemia. During childhood and 
adolescence, failure to thrive, growth retardation, rickets, and nephrolithiasis or 
nephrocalcinosis may occur and lead to the initial diagnosis. Patients may also 
develop polyuria which may be triggered by the reduced capacity to concentrate 
urine due to hypercalciuria, hypokalemia or nephrocalcinosis [19-21].  
 
 
Incomplete dRTA presents also with inadequate urinary acidification but 
patients usually have normal blood gases, i.e. normal blood pH and bicarbonate. The 
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defect can be revealed with the various types of acid challenge tests (ammonium 
chloride or fludrocortisone-furosemide test, see below) where urine pH does not 
acidify below 5.3 [22]. 
 
To date, mutations in genes encoding for three distinct transport proteins have been 
identified to cause classic dRTA: in the chloride-bicarbonate exchanger AE1/SLC4A1 
or in the B1/ATP6V1B1 and a4/ATP6V0A4 subunits of the vacuolar-type H+-ATPase 
[5-6,23-24]. However, not all cases of inborn dRTA can be explained by mutations in 
these genes suggesting that mutations in additional genes may contribute to 
inherited dRTA. Candidate genes may include the K+/Cl--cotransporter KCC4 
(SLC12A7) [25], the Forkhead transcription factor Foxi1 [26], the Cl-/HCO3- -
exchanger SLC26A7 [27], the ammonia channel RhCG (SLC42A3) [8], the hensin 
(DMBT1)-CXCL12 signal complex [28-29], or other H+-ATPase subunits [30]. In 
Europe, mutations in ATP6V1B1 and ATP6V0A4 appear to be more prevalent 
whereas in other regions, the relative occurrence of mutations may be different.  
 
 Mutations in SLC4A1 can be inherited in an autosomal dominant manner 
(heterozygous mutations) but also with an autosomal recessive inheritance 
(homozygous mutations). In contrast, mutations in the ATP6V1B1 and ATP6V0A4 
genes follow an autosomal recessive pattern but the significance of heterozygous 
mutations (i.e. only one mutated allele detectable) has recently been discussed (see 
below)[31].  
 
 The proton pump consists of a protein complex of two major domains, the 
cytosolic catalytic V1 domain hydrolyzing ATP (with 8 subunits A-H) and the 
membane-bound V0-Domäne mediating the proton transfer with the a, c, c“, d, and e 
subunits [32]. The B1 subunit is part of the V1-domain whereas the a4 subunit 
belongs to the V0-domain (Figure 2). The B1 subunit is found only in a few organs 
including kidney, inner ear, epididymis and lung. In kidney, the B1 subunit is highly 
enriched in all types of intercalated cells but is also detected at lower levels in the 
thick ascending limb of Henle. The a4 subunit is also enriched in all types of 
intercalated cells but is also highly abundant in the proximal tubule and in the thick 
ascending limb of the loop of Henle [33]. The subunit is also expressed in epididymis 
and the stria vascularis of the inner ear [24,34]. The expression of both subunits, B1 
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and a4, in the inner ear may explain the occurrence of sensorineural deafness in 
patients with mutations in these subunits. Nevertheless, the progression of 
sensorineural deafness is variable in patients and does not respond to alkali therapy 
[35-36]. Some patients may also develop dizziness possibly because of an enlarged 
vestibular aqueduct (EVA) observed in some but not all patients [36]. Whether 
alterations in the function of proton pumps in the epididymis occur and affect male 
fertility in these patients has remained unknown. 
 
Based on experiments in yeast and cell culture models it appears that most of 
the mutations identified in the B1 subunit cause either dysfunction or impaired 
assembly of the protein complex [37-38]. Accordingly, mice lacking the B1 subunit 
have a reduced capacity to acidify urine and develop more severe metabolic acidosis 
when acid-loaded. When crossed with hypercalciuric mice, B1 deficient mice develop 
severe nephrocalcinosis with hydronephrosis [39,19,40]. 
Lack of the a4 subunit in mice causes severe dRTA with hypokalemia, 
nephrocalcinosis, and reduced bone mineral density [41-42]. The mice develop also 
a massive hearing loss and a reduced sense of smell. The absence of the a4 subunit 
from the proximal tubule is associated with low molecular weight proteinuria 
suggesting an important role of this subunit in receptor-mediated endocytosis [42]. In 
at least one series of patients with mutations in either ATP6V1B1 or ATP6V0A4, 
mutations in the latter were associated with a more severe clinical presentation and 
reduced kidney function [42].  
 
 The chloride-bicarbonate exchanger AE1 (SLC4A1) is expressed both in acid-
secretory type A intercalated cells and red blood cells. Mutations in SLC4A1 cause 
either dRTA or red blood cell abnormalities including spherocytosis or South-East 
Asian ovalocytosis (SAO). Importantly, most mutations cause either dRTA or 
hematological abnormalities but only few mutations affect both systems. The mode of 
inheritance is usually autosomal dominant but few autosomal recessive mutations 
have been described. The most frequent recessive mutation, G701D, causes dRTA 
that can be associated with hemolytic anemia. Interactions of AE1 with the 
chaperone glycophorin have been identified to underlie the separation of renal and 
red blood cell mutations as this molecule is only expressed in red blood cells and is 
able to rescue "renal" mutations bringing them to the red blood cell membrane [43]. A 
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series of additional mutations has been identified that are more common in South-
East Asia and are mostly associated with a red blood cell phenotype. It has been 
speculated that some of these mutations may confer resistance to malaria [44]. In 
contrast to the recessive mutations, patients with a Caucasian background harbor 
more frequently dominant mutations, the R589H being the most common one, that 
rather causes dRTA [45-46]. Several types of AE1 mutations have been described 
that may cause either intracellular retention of mutant proteins or even mistargeting 
to the luminal membrane of type A intercalated cell models [47-49]. In mice, complete 
absence of AE1 causes severe metabolic acidosis and reduced renal excretion [50]. 
Introduction of the R589H mutation in mice (in mice this mutation corresponds to 
R607H) causes dysfunction of intercalated cells with reduced expression of proton 
pumps [45]. 
 
INHERITED DISTAL RENAL TUBULAR ACIDOSIS AS AN UNDERLYING CAUSE 
OF NEPHROCALCINOSIS OR KIDNEY STONES IN ADULTS 
 
Nephrocalcinosis is caused by various disorders with different pathophysiologies 
including e.g. primary hyperoxalurias, sarcoidosis, medullary sponge kidney, primary 
hyperparathyroidism, distal RTA and others. Depending on the underlying cause 
patients may develop chronic kidney disease (CKD) with progression to end stage 
kidney disease requiring renal replacement therapy. Thus, correct and timely 
diagnosis is of prime importance. Clinical manifestation of inherited dRTA can vary 
among patients depending on the underlying gene mutation. Hereditary recessive 
distal RTA due to B1 or a4 subunit mutations of the H+-ATPase typically manifests 
during infancy or childhood and presents with severe symptoms such as vomiting, 
failure to thrive, diarrhea or constipation, polyuria, nephrocalcinosis or 
rickets/osteomalacia. However, few cases may present with milder symptoms 
including a mild metabolic acidosis, hypocitraturia, incidental detection of kidney 
stones or renal calcification. Particularly, patients with autosomal dominant distal 
RTA due to mutations in the SLC4A1 gene may present first clinical symptoms only 
during adulthood.  
As a consequence of metabolic acidosis skeletal buffers such as carbonate and 
phosphate in combination with calcium are removed from the bones resulting in bone 
demineralization and subsequently in hypercalciuria. Additionally, expression of renal 
calcium transport proteins is decreased in metabolic acidosis further promoting 
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calcium excretion and thus development of nephrocalcinosis and kidney stones 
(Figure 3) [19,51].  
Consequently, in patients with nephrocalcinosis or repetitive episodes of kidney 
stones distal RTA is an important differential diagnosis and should be considered, 
particularly if stone analysis detects calcium phosphate containing stones in 
presence of metabolic acidosis or if there is evidence of impaired hearing or 
deafness.  
 
DIAGNOSIS OF INHERITED dRTA 
 
 Distal RTA results from a defective urinary acidification and is characterized by 
an inappropriate alkaline urine pH in the context of a hyperchloremic, normal anion 
gap metabolic acidosis with preserved GFR. The mutated genes, namely B1 
(ATP6V1B1) and a4 (ATP6V0A4) subunit as well as AE1 (SLC4A1), are also 
expressed in extrarenal tissues, including the epididymis and cells of the stria 
vascularis of the inner ear (B1 and a4), and erythrocytes (AE1), respectively. The 
diagnosis is primarily based on typical clinical and laboratory abnormalities and 
confirmed by genetic analysis. The phenotype includes renal and extrarenal clinical 
symptoms. Specialized tests to test for urinary acidification capacity are mentioned 
below and are mainly required for diagnosis of incomplete forms of dRTA. 
 
Short ammonium chloride loading test  
 Diagnosis of the renal defect is established by the short ammonium chloride 
loading test (= the short test of urinary acidification) that has been refinded and 
validated by Wrong and Davies in a seminal study several decades ago [22]. The 
principle of the short ammonium chloride loading test is based on the principal 
mechanism of hydrogen ion or acid secretion by the « healthy» kidney, namely 
excretion of all hydrogen ions combined with ammonia (NH3) as ammonium (NH4+). 
Meanwhile, several animal studies have confirmed the crucial role of 
ammoniagenesis and ammonium excretion in renal acid excretion [52-55]. 
The original protocol of the test is explained briefly: After emptying the bladder, urine 
is collected hourly under paraffin oil and thymol or toluene for 10 hours. After two 
hourly collections of urine, ammonium chloride capsules are given orally at a dose of 
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0.1 g (≈ 1.9 meq) per kg body weight over an hour. Blood gas analysis is performed 
before and after two to four hours after ingestion of ammonium chloride. Urinary pH is 
measured hourly using a pH electrode. In this test, urinary pH below 5.3 excludes an 
urinary acidification defect and the test is terminated. Wrong and Davies had 
investigated a total of 68 subjects, 10 healthy controls and 58 patients with different 
forms of renal diseases, including general renal failure without evidence of tubular 
abnormality, complete or incomplete renal tubular acidosis, and prolonged 
hypercalcemia and others. By using the ammonium chloride test, the authors 
demonstrated that the test is a reliable method to evaluate the ability of the kidney to 
excrete acid. Recently the test has been applied in several human studies [56-58]. 
Mostly, it has been used to selectively screen for complete or incomplete forms of 
distal renal tubular acidosis in recurrent kidney stone formers [57-58]. However, 
although the ammonium chloride loading test is still the «gold standard» to test for 
defective urinary acidification, many patients suffer from unpleasant gastrointestinal 
side effects of ammonium chloride such as nausea and vomiting and also are not 
pleased about the duration of the test for a maximum of 8 hours. Thus, Walsh et al. 
developed a more simple but effective, and well-tolerated alternative test that will be 
discussed in detail in the next paragraph.   
 
The simultaneous furosemide and fludrocortisone test as an alternative to 
ammonium chloride 
 
The simultaneous furosemide plus fludrocortisone test (f+f test) is based on 
previous studies describing a stimulation of H+ secretion in response to oral 
furosemide application [59]. The f+f test has been tested in complete and incomplete 
dRTA and it is less specific than the gold standard ammonium chloride test. The test 
is thought to be based on the stimulation of electrogenic sodium reabsorption by the 
epithelial sodium channel ENaC in the collecting duct system due to enhanced 
delivery of sodium after blockade of Na+-reabsorption by the loop diuretic furosemide 
in the TAL [60]. Higher activity of ENaC would cause a more lumen-negative potential 
in the collecting duct system and thereby increase the driving force for proton 
secretion. The mineralocorticoid fludrocortisone would stimulate ENaC activity but 
also direct effects of aldosterone on H+-ATPase activity have been described [61-62]. 
More recently, an alternative explanation has been provided whereby furosemide 
would stimulate NHE3-dependent proton secretion in the TAL and thereby increase 
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urinary acidification [63]. Why TAL proton secretion would be reduced in dRTA 
patients is unclear but could be related to the expression of the ATP6V1B1 and 
ATP6V0A4 transcripts in the TAL [33]. However, a more recent study conducted in 
healthy human volunteers provides support for the initial hypothesis that furosemide 
–induced urinary acidification requires ENaC-activity as the furosemide-induced drop 
in urinary pH was blunted when the ENaC-inhibitor amiloride was coadministered 
[64]. 
In a first study with the f+f test, Walsh et al. investigated 8 patients with 
previously diagnosed dRTA and a control group of 11 healthy probands [56]. All 
participants were subjected to a short ammonium chloride test followed by the f+f 
test. Briefly, a baseline urine sample was collected from all participants followed by 
oral administration of 40mg furosemide and 1mg fludrocortisone. Urine collection was 
performed hourly and urine pH was measured using an electrode pH meter for 6 
hours after the baseline sample. Notably, there were no adverse effects with the f+f 
test. All healthy probands were able to acidify their urine below pH 5.3 with the f+f 
test or the ammonium chloride test while urine pH of dRTA patients remained above 
pH 5.3 indicating defective urinary acidification. In a follow-up study the f+f test was 
further used  in a preselected cohort of kidney stone formers [57]. In this study the 
authors confirmed a distinct sensitivity and excellent negative predictive value of this 
test to exclude incomplete dRTA in patients with kidney stones or nephrocalcinosis or 
both. However, this study was retrospectively performed and only patients with a 
clinical suspicion for an acidification defect were tested. Consequently, the reliability 
of the f+f test, especially in the diagnosis of incomplete dRTA, remains to be further 
validated by ideally a prospective blinded study in a cohort of unselected patients. 
Additionally due to limited specificity patients tested negative with f+f test may require 
confirmation by the ammonium chloride loading test. This finding has also been 
confirmed in another study by Dhayat and colleagues who prospectively subjected an 
unselected cohort of 170 stone formers to sequential ammonium chloride and f+f 
testing [65]. Furthermore, the authors also tested for non-provocative laboratory 
parameters to predict incomplete dRTA and could demonstrate by using a morning 
fasting urinary pH at a threshold of > 5.3 with a plasma potassium threshold of > 3.8 
mmol/l that incomplete dRTA can reliably be excluded. Thus, future studies are 
required to verify the value and impact of the f+f test in diagnosing  incomplete dRTA.  
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Hearing test 
The ATP6V1B1 and ATP6V0A4 are also expressed in extrarenal tissues such 
as in the stria vascularis of the inner ear. Thus, the majority of patients with the 
recessive forms of dRTA develop progressive bilateral sensorineural hearing loss 
which is interestingly more common in patients with B1 mutations than in subjects 
with a4 mutations [46,35,6,41-42]. Some patients also present with other 
abnormalities of the auricular system such as abnormal widening of the vestibular 
aqueduct (enlarged vestibular aqueduct, EVA) which is usually bilaterally present 
(Figure 4) [36]. However, this type of abnormalities is not specific for hereditary 
dRTA since they may also be present in patients with Pendred or Branchio-oto-renal 
syndrome.  
To test for sensorineural hearing abnormalities a standard audiogram has to 
be performed investigating masked and unmasked bone and air conduction at 
different frequencies. To detect other auricular abnormalities, both, MRI or CT can be 
used for the diagnosis of enlarged vestibular aqueducts (Figure 4) [36].  
Patients with inherited dRTA due to mutations in SLC4A1 may present 
concomitantly with Southeast Asian ovalocytosis (SAO), mainly in the Malay 
archipelago, the Philippines, Indonesia and southern Thailand. SAO is a hematologic 
disease that is clinically characterized by hemolytic anemia, oval shape erythrocytes 
in the peripheral blood smear, and the presence of the hemizygous deletion of amino 
acids 400-408 (also known as SAO mutation) [66]. 
 
LONG-TERM PERSPECTIVES 
 
Clinical outcome/ Progression to CKD 
 
To date, very few data exist on long-term clinical outcome of inherited dRTA 
patients. Most studies have primarily investigated the genotype-phenotype 
characteristics of these patients at diagnosis. The most recent report has investigated 
one of the largest cohorts of patients with dRTA so far [67]. Among 89 patients 
clinically diagnosed with inherited dRTA, mutations in ATP6V1B1, ATP6V0A4, and 
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SLC4A1 were found in 71.9% of all subjects. There was no significant difference 
regarding male and female distribution for all genes. Mean age of onset was around 
5.5 years, however, patients with SLC4A1 mutations typically present at an older age 
(12-13 years-old) compared to subjects with ATP6V1B1 and ATP6V0A4 mutations. 
As expected, sensorineural hearing loss was present in the majority of cases with 
ATP6V1B1 (92%) and ATP6V0A4 (56.7%) mutations, with a significantly earlier 
onset in patients carrying the ATP6V1B1 mutation. Another common finding was 
nephrocalcinosis that was detected in 93.6% of all mutated patients without 
differences among the different types of mutated genes. In this cohort, hypokalemia 
was more frequent and severe in patients with H+-ATPase mutations compared to 
subjects with SLC4A1 mutations. Notably, a significant proportion of subjects with 
pathogenic mutations (31.3%) suffered from chronic kidney disease (CKD, defined 
according to the KDIGO criteria: eGFR < 90 ml/min/1.73m2) during the long-term 
follow-up, presenting after pubertal growth spurt. These findings are novel and of 
particular importance since inherited dRTA was always considered as a “benign” 
disease with regard to kidney function [46]. However, the pathophysiology of CKD is 
unclear and has been discussed to be caused by tubulo-interstitial damage due to 
nephrocalcinosis and persistent hypokalemia. In addition, repeated pre-renal hits with 
acute kidney injury may also result in chronic kidney damage. Further studies are 
required to confirm these findings in larger cohorts. A previous smaller study 
including 19 children with genetically confirmed inherited dRTA also reported earlier 
age of onset in patients with ATP6V1B1 and ATP6V0A4 mutations compared to 
subjects with SLC4A1 mutations [46]. Metabolic acidosis was more profound in 
children with ATP6V0A4 mutations. Interestingly, in this cohort a substantial number 
of patients presented with partial proximal tubular dysfunction (partial Fanconi 
syndrome) that resolved after alkali treatment. However, the underlying mechanisms 
are unclear and have been discussed to be associated with the role of the proton 
pump in receptor-mediated endocytosis, and the co-expression of the a4 subunit 
together with the chloride transporter CLC-5 in the proximal tubule cells and α-
intercalated cells of the collecting ducts [68]. As described by Palazzo et al., 
nephrocalcinosis was very common and detected in all but one patient and reported 
to present with different degrees (mild to moderate or marked). In addition, 3 patients 
developed kidney stones while there was no correlation between the severity of 
nephrocalcinosis and development of kidney stones. Also in this cohort a significant 
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number of the children presented with CKD (KDIGO G2, eGFR of 60-90 
ml/min/1.73m2) at last follow-up (at the age of up to 15 years). There was no 
significant correlation between the genetic diagnosis and CKD, however, there was a 
trend towards ATP6V0A4 mutations being more common in patients with CKD at last 
follow-up. This observation is supported by animal data from Atp6v0a4-deficient mice 
that demonstrated impaired proximal tubule function [42]. Furthermore, in this study 
data analysis from a total of 99 patients with ATP6V1B1 and ATP6V0A4 mutations 
demonstrated a more severe phenotype in patients with ATP6V0A4 mutations 
compared to patients carrying the ATP6V1B1 mutation.  
In summary, clinical outcome of inherited dRTA patients seems to be good, 
particularly if diagnosis was established early with subsequent initiation of alkali 
treatment. In contrast to frequent presence of nephrocalcinosis and kidney stones in 
this population, some patients may develop CKD. The underlying mechanisms of 
CKD have not been fully identified yet and seem to be associated with the respective 
gene. Further studies are required with larger patient cohorts and longer follow-ups, 
especially from the time period after transition to adult care, to evaluate the risk to 
progress to end-stage renal disease.  
 
Pregnancy 
Female CKD patients are at increased risk for complications during pregnancy 
and therefore intensive monitoring and interdisciplinary care is highly recommended 
in this population [69-71]. However, patients with inherited dRTA usually have a 
normal kidney function with preserved estimated GFR (eGFR) and therefore are 
often not perceived as CKD patients. Nevertheless, several case reports have 
described severe complications during pregnancy in female patients with different 
types of RTA [72-75]. We have recently reported a series of three pregnant women 
with inherited dRTA with exacerbated acid-base disturbances during pregnancy [76]. 
All three patients presented with profound hypokalemia and worsening of metabolic 
acidosis during pregnancy. In addition to a potentially higher requirement for alkali 
therapy and potassium supplementation during pregnancy, physicians have to pay 
particular attention to hyperemesis gravidarum that might be a cause of stopping 
intake of alkali therapy and subsequent deterioration of acid- base and electrolyte 
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status. Other complications such as recurrent urinary tract infections and obstruction 
should also be considered because of pre-existing nephrocalcinosis and/or kidney 
stones. Consequently, in pregnant women with inherited dRTA interdisciplinary 
management including the obstetrician and the nephrologist is recommended. 
Furthermore, in addition to regular monitoring of creatinine and proteinuria, acid-base 
and electrolyte status should also be tested regularly to prevent life-threatening 
hypokalemia and decompensation of metabolic acidosis.  
 
Stone risk in heterozygous carriers? 
A recent study from Dhayat et al. has investigated the in vivo impact of a 
single-nucleotide polymorphism (SNP) in the coding region of the B1 subunit causing 
a change in amino acid sequence (c.481G.A; p.E161K) of the H+-ATPase that 
causes greatly diminished pump function in vitro, and on urinary acidification in 
recurrent kidney stone formers [58]. Among 555 patients with stone disease, 5.8% 
were heterozygous for the respective SNP and demonstrated a trend to higher 
urinary pH values. 52.4% of the patients with p.E161K SNP were even identified with 
incomplete dRTA by using the short NH4Cl loading test to confirm a urinary 
acidification defect in these patients (= urine pH > 5.3). As expected, there was a 
higher prevalence of calcium phosphate stones in p.E161K carriers when compared 
to wild-type subjects. As mentioned above, the simultaneous furosemide and 
fludrocortisone test is a valid alternative to the ammonium chloride test. Thus, Shavit 
et al. compared the results of both f+f and short NH4Cl test from recurrent stone 
formers who were screened for dRTA [57]. Urinary acidification defect as a result of 
incomplete or complete dRTA was present in 50% of the 34 patients that were 
subjected to both tests. The comparison of both tests revealed a sensitivity of 100% 
but a specificity of only 24% for the f+f test. Therefore in patients with abnormal f+f 
test who are clinically not suspicious of defective urinary acidification, confirmation by 
NH4Cl test should be performed.  
 
THERAPY OF INHERITED DRTA 
 
To date, therapy of inherited dRTA consists of alkali treatment to correct 
metabolic acidosis and avoid complications such as failure to thrive, growth 
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retardation, and rickets [46]. Physicians have to consider that in contrast to adults 
that usually require stable and low doses of bicarbonate such as 0.5-1 mEq/kg/day, 
growing children and infants may need substantially higher doses, especially if 
genetic diagnosis includes mutations in the B1 or a4-subunit of the H+-ATPase 
compared to patients with SLC4A1 mutations. Unfortunately, there is no amelioration 
of the progressive hearing loss and progressive nephrocalcinosis by alkali therapy. 
Potassium containing formulations such as potassium citrate should be preferred 
since patients usually present with a hypokalemic metabolic acidosis. However, 
potassium citrate may be unpleasant for some patients because of gastrointestinal 
side effects, therefore also sodium bicarbonate or other alkali formulations can be 
used or added to therapy. Pediatricians may also use Shohl’s solution containing 
sodium citrate that can be easier dose-adjusted in children. In the presence of severe 
hypercalciuria thiazides can be administered to reduce renal calcium excretion, 
however, they should be used carefully since the risk of hypokalemia and polyuria 
may increase. If polyuria is severe indomethacin can be added to therapy.  
Because of progressive and irreversible hearing loss hearing devices and 
language teaching are inevitable and thus of prime importance to ensure normal 
intellectual development and social integration of these patients.  
 
SUMMARY AND CONCLUSION 
 dRTA is a rare inherited tubular disorder impairing the kidneys ability to acidify 
urine and excrete acid. The clinical manifestations depend on the gene mutated. In 
severe cases patients may present after birth with failure to thrive, vomiting, 
dehydration, and profound disturbances of acid-base balance and electrolytes. In 
milder cases, nephrocalcinosis or -lithiasis may be the first clinical presentations. 
Next to treatment of metabolic acidosis, the progressive loss of hearing should be 
treated with hearing aids to ensure a normal intellectual development of children. 
Early genetic diagnosis and counseling of parents is important. During pregnancy, 
women with dRTA may suffer from exacerbations of their metabolic acidosis and 
experience severe electrolyte disturbances requiring a close monitoring of these 
parameters.    
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Figure Legends 
 
Figure 1. Scheme of mechanisms underlying bicarbonate reabsorption in the 
proximal tubule. NBCe1 electrogenic Sodium-bicarbonate-cotransporter 1, NBCn2 
electroneutral Sodium-Bicarbonate-cotransporter 2, NHE3 Sodium-Proton-exchanger 
3, V-ATPase vacuolar-type H+-ATPase, CAII Carbonic anhydrase type II, CAIV 
Carbonic anhydrase type IV. 
__ 
 
Figure 2.  Type-A acid-secretory intercalated cells in the collecting system and 
structure of the V-type H+-ATPase (insert). The red/orange parts of the pump 
belong to the V1-partl, the blue subunits to the V0-sector; the B- and a-subunits, 
mutated in inherited dRTA, are indicated and occur in different isoforms. The B1 or 
a4 isoforms, respectively, can be mutated in patients with dRTA and 
nephrocalcinosis. AE1 „anion exchanger“ 1, RhCG „rhesus blood group family type C 
glycoprotein“, RhBG „rhesus blood group family type B glycoprotein“, CAII Carbonic 
anhydrase type II, V-ATPase vacuolar-type H+-ATPase) 
 
Figure 3. Medullary nephrocalcinosis as a typical feature of patients with 
inherited distal RTA: CT scan (left and center panel), plain abdominal radiography 
(right panel) 
 
Figure 4: Enlarged vestibular aqueduct in a patient with inherited dRTA:  
MRI images of the temporal bone and labyrinth with bilateral enlarged endolymphatic 
duct (arrow) (A). (B) Three-dimensional reconstruction of the labyrinth showing the 
enlarged endolymphatic duct and sac (arrow) and bulbous dysplasia of the apical 
turn of the cochlea (short arrow). Right (c) and left (d) temporal bone with 
enlargement of the bony vestibular aqueducts (long arrow) in comparison to the 
diameter of the posterior semicircular canal (short arrow). Taken from [36]. 
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